Eckhart Kaempgen

4.3k citations
21 papers · 1.0k indexed · h-index 13
Topics
Immunotherapy and Immune Responses (9 papers)CAR-T cell therapy research (6 papers)Cancer Immunotherapy and Biomarkers (5 papers)

In The Last Decade

Eckhart Kaempgen

21 papers receiving 1.0k citations

Peers

Eckhart Kaempgen
Comparison fields: 5 of 71
  • Immunology 591
  • Oncology 578
  • Molecular Biology 471
  • Genetics 204
  • Ophthalmology 116
Replace Volker Lennerz with:
Volker Lennerz Germany
Yutaka Kawakami Japan
Christopher R. Zito United States
Simone Gaedicke Germany
Kay Stubenrauch Germany
Namir J. Hassan United Kingdom
Justin D. Saco United States
Tobias Schimming Germany
Smita S. Chandran United States
Eckhart Kaempgen relative to Volker Lennerz Germany Volker Lennerz's profile →
Citations per field
00.5×10×12.9×
Volker Lennerz · 1×
Citations per year

Countries citing papers authored by Eckhart Kaempgen

Since Specialization
Citations

This map shows the geographic impact of Eckhart Kaempgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eckhart Kaempgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eckhart Kaempgen more than expected).

Fields of papers citing papers by Eckhart Kaempgen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eckhart Kaempgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eckhart Kaempgen. The network helps show where Eckhart Kaempgen may publish in the future.

Co-authorship network of co-authors of Eckhart Kaempgen

This figure shows the co-authorship network connecting the top 25 collaborators of Eckhart Kaempgen. A scholar is included among the top collaborators of Eckhart Kaempgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eckhart Kaempgen. Eckhart Kaempgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 2
2 18
3 92
4 93
5 68
6 15
7 89
8 35
9 8
10 4
11 5
12 2
13 2
14 44
15 205
16 62
17 87
18 137
19 64
20 1

About Eckhart Kaempgen

Eckhart Kaempgen is a scholar working on Ophthalmology, Immunology and Oncology, having authored 21 papers that have together received 1.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (9 papers), CAR-T cell therapy research (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). The work is most often cited by research in Immunology (591 citations), Oncology (578 citations) and Genetics (204 citations). Eckhart Kaempgen has collaborated with scholars based in Germany, Belgium and United States. Frequent co-authors include Johannes Wolff, Philippe Demaerel, Steven De Vleeschouwer, Stefan Rutkowski, Frank Van Calenbergh, Gerold Schuler, Monika Warmuth‐Metz, Stefaan W. Van Gool, Raf Sciot and Patrick Flamen. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026